Study of ABT-700 in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2017-04-27
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and
preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET
amplification or c-Met overexpression. ABT-700, previously known as h224G11 in publications,
is an anti-c-Met antibody. The early clinical development plan for ABT-700 is based on the
activity demonstrated in preclinical models. Up to 124 subjects will be enrolled.